Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle

Chang Yeol Lee; Yonghao Ma; Yong Sung You; Hyoung Eun Kim; Young Dook Byeon; Hyungil Jung

doi:10.1007/s13206-015-9305-9

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle

Chang Yeol Lee, Yonghao Ma, Yong Sung You, Hyoung Eun Kim, Young Dook Byeon, Hyungil Jung

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.

Original language	English
Pages (from-to)	232-238
Number of pages	7
Journal	Biochip Journal
Volume	9
Issue number	3
DOIs	https://doi.org/10.1007/s13206-015-9305-9
Publication status	Published - 2015 Sep 28

All Science Journal Classification (ASJC) codes

Biotechnology
Bioengineering
Biomedical Engineering
Electrical and Electronic Engineering

Access to Document

10.1007/s13206-015-9305-9

Fingerprint Dive into the research topics of 'Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle'. Together they form a unique fingerprint.

Cite this

@article{e77f805c5cef4b728b4594c06471c933,

title = "Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle",

abstract = "Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.",

author = "Lee, {Chang Yeol} and Yonghao Ma and You, {Yong Sung} and Kim, {Hyoung Eun} and Byeon, {Young Dook} and Hyungil Jung",

year = "2015",

month = sep,

day = "28",

doi = "10.1007/s13206-015-9305-9",

language = "English",

volume = "9",

pages = "232--238",

journal = "Biochip Journal",

issn = "1976-0280",

publisher = "Springer-Verlag GmbH and Co. KG",

number = "3",

}

TY - JOUR

T1 - Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle

AU - Lee, Chang Yeol

AU - Ma, Yonghao

AU - You, Yong Sung

AU - Kim, Hyoung Eun

AU - Byeon, Young Dook

AU - Jung, Hyungil

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.

AB - Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.

UR - http://www.scopus.com/inward/record.url?scp=84942304308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942304308&partnerID=8YFLogxK

U2 - 10.1007/s13206-015-9305-9

DO - 10.1007/s13206-015-9305-9

M3 - Article

AN - SCOPUS:84942304308

VL - 9

SP - 232

EP - 238

JO - Biochip Journal

JF - Biochip Journal

SN - 1976-0280

IS - 3

ER -